 SAN DIEGO, Nov. 16, 2020 GLOBE NEWSWIRE -- Adamis Pharmaceuticals Corporation NASDAQ: ADMP Adamis today announced that after the close of business and the U.S. markets on November 13th, it received a Complete Response Letter CRL from the U.S. Food and Drug Administration FDA regarding its New Drug Application NDA for Adamis ZIMHITM high dose naloxone injection product for the treatment of opioid overdose. The CRL stated that the FDA determined it cannot approve the NDA in its present form and provided recommendations needed for resubmission. 